HELIUS MEDICAL TECHNOLOGIES (HSDT)
US42328V8019 - Common Stock
We assign a fundamental rating of 3 out of 10 to HSDT. HSDT was compared to 191 industry peers in the Health Care Equipment & Supplies industry. HSDT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HSDT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year HSDT has reported negative net income.
In the past 5 years HSDT always reported negative net income.
HSDT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
HSDT has a worse Return On Assets (-115.05%) than 83.25% of its industry peers.
HSDT has a worse Return On Equity (-376.60%) than 86.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.05% | ||
| ROE | -376.6% | ||
| ROIC | N/A |
ROA(3y)-108.35%
ROA(5y)-127.05%
ROE(3y)-236.75%
ROE(5y)-248.57%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of HSDT (9.47%) is worse than 84.29% of its industry peers.
In the last couple of years the Gross Margin of HSDT has declined.
The Profit Margin and Operating Margin are not available for HSDT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 9.47% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-38.59%
GM growth 5Y-37.58%
2. Health
2.1 Basic Checks
The number of shares outstanding for HSDT has been increased compared to 1 year ago.
Compared to 5 years ago, HSDT has more shares outstanding
HSDT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -33.14, we must say that HSDT is in the distress zone and has some risk of bankruptcy.
HSDT has a worse Altman-Z score (-33.14) than 91.10% of its industry peers.
HSDT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -33.14 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 3.96 indicates that HSDT has no problem at all paying its short term obligations.
With a Current ratio value of 3.96, HSDT perfoms like the industry average, outperforming 59.16% of the companies in the same industry.
HSDT has a Quick Ratio of 3.72. This indicates that HSDT is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.72, HSDT is doing good in the industry, outperforming 67.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.96 | ||
| Quick Ratio | 3.72 |
3. Growth
3.1 Past
HSDT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.30%, which is quite impressive.
HSDT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.17%.
HSDT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.05% yearly.
EPS 1Y (TTM)79.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.56%
Revenue 1Y (TTM)-18.17%
Revenue growth 3Y-0.81%
Revenue growth 5Y6.05%
Sales Q2Q%21.62%
3.2 Future
Based on estimates for the next years, HSDT will show a very strong growth in Earnings Per Share. The EPS will grow by 29.30% on average per year.
HSDT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 142.98% yearly.
EPS Next Y61.41%
EPS Next 2Y33.7%
EPS Next 3Y29.3%
EPS Next 5YN/A
Revenue Next Year-7.05%
Revenue Next 2Y31.4%
Revenue Next 3Y199.56%
Revenue Next 5Y142.98%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HSDT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSDT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as HSDT's earnings are expected to grow with 29.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.7%
EPS Next 3Y29.3%
5. Dividend
5.1 Amount
No dividends for HSDT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HELIUS MEDICAL TECHNOLOGIES
NASDAQ:HSDT (6/14/2024, 7:14:31 PM)
After market: 1.01 0 (-0.01%)1.0101
-0.05 (-4.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.56M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.05% | ||
| ROE | -376.6% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 9.47% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.96 | ||
| Quick Ratio | 3.72 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)79.3%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y61.41%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-18.17%
Revenue growth 3Y-0.81%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y